Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 9, 2020, Sierra Oncology, Inc. (the "Company") held its 2020 Annual Meeting of Stockholders and the following proposals were adopted:





    1.   Election of three Class II Directors, Andrew Allen, Mona Ashiya and
         Andrew Sinclair, each to serve a three-year term, which will expire at
         the 2023 Annual Meeting of Stockholders and until such time as their
         respective successors have been duly elected and qualified or until such
         director's earlier resignation or removal. The vote tally was as follows:




           Nominees       Shares For       Shares Withheld       Broker Non-Votes
        Andrew Allen        7,804,443               273,053              1,678,526
        Mona Ashiya         8,051,616                25,880              1,678,526
        Andrew Sinclair     8,044,510                32,986              1,678,526




    2.   Ratification of the appointment of Deloitte & Touche LLP as the Company's
         independent registered public accounting firm for the fiscal year ending
         December 31, 2020. The vote tally was as follows:




         Shares For       Shares Against       Shares Abstaining        Broker Non-Votes
           9,722,080               14,238                   19,704                       -

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses